Research location
Ashford
South Australia, Australia
Advertisement
Research activity in Ashford
South Australia, AustraliaCureCurrent currently publishes aggregate city-level research activity for this location: 18 trials and 18 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ashford
18 linked trials · page 1 of 1Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyNCT04655976 · 2020-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyNCT03037931 · 2017-03-15 · 1 site observation
COMPLETED
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)NCT03057977 · 2017-03-06 · 1 site observation
COMPLETED
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)NCT03057951 · 2017-03-02 · 1 site observation
COMPLETED
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · 2017-01-06 · 1 site observation
COMPLETED
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk FactorsNCT02019264 · 2014-01-24 · 1 site observation
COMPLETED
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).NCT01131676 · 2010-07-01 · 1 site observation
COMPLETED
Phase 3 Study of Immunotherapy to Treat Advanced Prostate CancerNCT01057810 · 2010-07-01 · 1 site observation
COMPLETED
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabNCT00625898 · 2008-04-01 · 1 site observation
TERMINATED
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate CancerNCT00617669 · 2008-01-01 · 1 site observation
COMPLETED
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone MetastasesNCT00554229 · 2007-11-01 · 1 site observation
COMPLETED
Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate CancerNCT00268593 · 2005-08-01 · 1 site observation
COMPLETED
Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mgNCT00242775 · 2005-05-01 · 1 site observation
COMPLETED
Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)NCT00102804 · 2005-03-01 · 1 site observation
COMPLETED
Androgen Deprivation Therapy in Treating Patients With Prostate CancerNCT00110162 · 2004-10-01 · 1 site observation
UNKNOWN
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)NCT00090363 · 2004-07-01 · 1 site observation
COMPLETED
A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung CancerNCT00190840 · 2003-09-01 · 1 site observation
COMPLETED
A Phase III Trial For Patients With Metastatic Breast CancerNCT00191152 · 2002-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.